Master Rollover Protocol for Continued Safety Assessment... | NCT02632994

Studies
Master Rollover Protocol for Continued Safety Assessment of Study Drug

NCT02632994

Sponsor

Eli Lilly and Company

Status

Available

Last Update Posted

Jun 25, 2026Actual

Enrollment

Not provided

Phase

Not provided

Conditions

Cancer

Interventions

LY2503029
LY3023414
LY3838915
LY3847429

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

ID	Type	Description	Link
I8I-MC-JYAA	Other Identifier	Eli Lilly and Company

Status Module

Record Verification Date

Jun 2026

Overall Recruitment Status or Expanded Access Status

Available

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Not provided

Primary Completion Date

Not provided

Completion Date

Not provided

First Submitted Date

Dec 15, 2015

First Submission Date that Met QC Criteria

Dec 15, 2015

First Posted Date

Dec 17, 2015Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Jun 22, 2026

Last Update Posted Date

Jun 25, 2026Actual

Description Module

Brief Summary

This study is for patients who have participated in a previous study and who continue to receive benefit to have continued access to study drug and/or treatment.

Detailed Description

Not provided

Design Module

Study Type

Expanded Access

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

No data available

No data is available for this block.

Biospecimen

No data available

No data is available for this block.

Enrollment

Not provided

Arms/Interventions Module

Arm Groups

Not provided

Interventions

Name	Type	Description
LY2503029	Drug	Administered orally.
LY3023414	Drug	Administered orally.
LY3838915	Drug	Administered orally.
LY3847429	Drug	Administered orally.

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

To be eligible patients must be currently receiving benefit in a concluded Lilly study for a compound that has opened an addendum in the continued access protocol.

Exclusion Criteria:

Patients must not be concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.

Accepts Healthy Volunteers

Not provided

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

18 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or	Contact	1-317-615-4559		LillyTrials@Lilly.com
Physicians interested in becoming principal investigators please contact	Contact			clinical_inquiry_hub@lilly.com

Overall Officials

Name	Affiliation	Role
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)	Eli Lilly and Company	Study Director

Locations

Facility	Status	City	State	ZIP	Country	Contacts
UCLA Medical Center	Available	Torrance	California	90505	United States